DHCR7-DT and bone cancer: Furthermore, we found that XZP treatment significantly reduced the levels of serum TRACP5b, CIPT, PINP, and BAP and the AP+ osteoblasts and TRAP+ osteoclasts in rats, related to that of placebo group, demonstrating that XZP treatment mitigated the bone cancer-induced aberrant activation of osteoclasts and osteoblasts.